Eficacia y seguridad de carfilzomib más dexametasona en pacientes adultos con mieloma múltiple en recaída o refractario que han recibido 2 o 3 regimenes de tratamiento previos (incluidos lenalidomida y bortezomib) con refractariedad a lenalidomida / Efficacy and safety of carfilzomib plus dexamethasone in adult patients with relapsed or refractory multiple myeloma who have received 2 or 3 prior treatment regimens (including lenalidomide and bortezomib) with refractoriness to lenalidomide
Lima; IETSI; mayo 2023.
Non-conventional
in Spanish
| BRISA/RedTESA
| ID: biblio-1553165
Responsible library:
BR1.1
Subject(s)
Full text:
Available
Collection:
Tematic databases
Database:
BRISA/RedTESA
Main subject:
Dexamethasone
/
Proteasome Inhibitors
/
Bortezomib
/
Lenalidomide
/
Multiple Myeloma
Type of study:
Health technology assessment
Limits:
Adult
/
Humans
Language:
Spanish
Year:
2023
Document type:
Non-conventional
